NMN and medications.

NMN (nicotinamide mononucleotide) and NR (nicotinamide riboside) are two different precursors of NAD+, a coenzyme used throughout the body's energy chemistry whose blood levels fall with age. We do not recommend either, for any goal. In Great Britain NMN is not yet authorised as a novel food, so it should not be on sale here as a supplement, although you may still see it sold; the duty to follow that rule sits with the seller, not with you, and the application to authorise it is still in progress, so this may change. NR is authorised here, but the two randomised trials of NR in our records that measured insulin sensitivity, both in overweight or obese adults, found no improvement in it. Human trials since 2020 consistently show NMN raises NAD+ or related compounds in the blood. What that raised level does is a narrower question, and our records grade neither substance for any goal. Neither is graded for energy: the NMN trial that measured this most directly, Pencina 2023, found no difference from placebo in muscle strength, fatigability, aerobic capacity or stair-climbing power. Neither is graded for longevity, because not one of the trials we cite measures lifespan, healthspan, frailty or biological age. A falling NAD+ level describes ageing; it does not show that topping it up changes how you age. The metabolic results that do exist all come from NMN: Yoshino 2021 found improved muscle insulin sensitivity in prediabetic women, and Pencina 2023 reported lower cholesterol, diastolic blood pressure and body weight, though in that trial insulin sensitivity did not change; it was funded by the company that makes the product tested, and several of its authors are employed by, consult for or hold shares in it. Any history of cancer is a hard exclusion for both: laboratory and animal studies suggest NAD+ precursors may help tumour cells survive and spread, and since no study in people has tested whether either changes the chance of cancer returning or a new one developing, we take the cautious side. If you already take NMN with diabetes medication, the interaction to raise is blood sugar: NMN may modestly improve how the body responds to insulin, so alongside gliclazide or injected insulin your blood sugar could in theory go lower than your dose is set for. We hold no study of that combination, and the NMN trials that measured insulin response enrolled people who were not taking diabetes medication, so treat it as a precaution rather than a finding: monitor your levels and speak to your diabetes team. In the trials we cite, side effects were few and no more common on NMN than on placebo.